Lingze Tablets for BPH with Kidney-Deficiency,blood Stasis and Dampness Resistance:A Phase-ⅳ Open-Label Single-Arm Multicenter Clinical Study and Safety Evaluation
Shao-Ying Yuan,Xiao-Yong Gong,Xiao-Jun Huang,Shao-Bo Jiang,Chao-Ba He,Yang Wang,Li-Guo Geng,Zhao-Lei Zhang,Wei-Guang Wang
DOI: https://doi.org/10.13263/j.cnki.nja.2021.08.011
2021-01-01
Abstract:OBJECTIVE:To evaluate the efficacy and safety of Lingze Tablets in the treatment of BPH with kidney deficiency, blood stasis and dampness resistance.METHODS:Totally 235 eligible BPH patients, aged 50-80 years and meeting the inclusion criteria, were enrolled and treated with Lingze Tablets orally, 4 tablets per time, tid. Before and after an 8-week course of medication, IPSS, quality of life (QOL) and TCM syndromes scores were obtained from the patients.RESULTS:Of the total number of patients, 211 completed the whole course of treatment. Compared with the baseline, the IPSS was dramatically reduced after 4 and 8 weeks of medication (18.28 ± 5.29 vs 12.82 ± 4.66 and 9.23 ± 4.21, P < 0.01), and so were the QOL scores (6.44 ± 1.99 vs 4.95 ± 1.64 and 3.16 ± 1.53, P < 0.01) and TCM syndromes scores (17.49 ± 5.30 vs 12.45 ± 3.74 and 9.17 ± 3.24, P < 0.01). The incidence rates of adverse events and drug-related adverse reactions were 15.2% and 1.9%, respectively, and no organ function impairment was observed.CONCLUSIONS:Lingze Tablets are definitely effective and safe for the treatment of BPH with kidney deficiency, blood stasis and dampness resistance.